If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
== Further reading == Aida, N.; Tamagawa, K.; Takada, K.; Yagishita, A.; Kobayashi, N.; Chikumaru, K.; Iwamoto, H. (April 1996). "Brain MR in Fukuyama congenital muscular dystrophy". American Journal of Neuroradiology. 17 (4): 605–613. PMC 8337276. PMID 8730178. Saito, Fumiaki; Matsumura, Kiichiro (December 2011). "Fukuyama-type congenital muscular dystrophy and defective glycosylation of α-dystroglycan". Skeletal Muscle. 1 (1): 22. doi:10.1186/2044-5040-1-22. PMC 3156645. Fukuyama type muscular dystrophy at NIH's Office of Rare Diseases
The two were together for eight months between 2015 and 2016. Kardashian began dating basketball player Tristan Thompson in 2016. Kardashian gave birth to a daughter, True Thompson, on April 12, 2018, amidst controversy after Thompson was found to have cheated on Kardashian during her pregnancy. In February 2019, Kardashian and Thompson split after it was revealed that Thompson had allegedly cheated on Kardashian with her younger half-sister Kylie Jenner's then-best friend Jordyn Woods. After quarantining together during the COVID-19 pandemic for the sake of their daughter, they ended up rekindling their relationship in August 2020. They became engaged in February 2021, but split for good in December 2021, when it was revealed that Thompson had cheated on Kardashian again in March 2021, and fathered a son who was born in December 2021. In July 2022, it was announced that Kardashian and Thompson were expecting a baby boy via surrogacy, who was conceived before Kardashian discovered Thompson's cheating. Their son, Tatum, was born on July 28, 2022.
=== Funding trajectory === Since 1999, the division's funding increased more than six-fold. By 2012, OAM and NCCAM spent a cumulative $1.6 billion in grant funding. Between 1999 and 2009, NCCAM supported approximately 50% of the National Cancer Institute spending on CAM, with the total amount spent on CAM during that time frame $2.856 billion. The NCCIH budget for 2005 was $123 million. For fiscal year 2009 (ending September 30, 2009), it was $122 million. The NIH has also conducted research in alternative medicine at the National Cancer Institute by the Office of Cancer Complementary and Alternative Medicine which, in 2009, had the same $122 million budget as NCCIH. For FY 2009; NIH's total budget was about $29 billion. The NCCIH budget for 2015 was $124.1 million. They requested a $3,459,000 funding increase for their 2016 budget. By FY2023, the NCCIH budget had grown to approximately $170 million annually. The FY2026 President's Budget proposed eliminating NCCIH entirely, but Congress rejected the proposal and maintained NCCIH funding at the FY2025 level.
Sources: en.wikipedia.org
Bioprinting can also be used for cultured meat. In 2021, a steak-like cultured meat, composed of three types of bovine cell fibers was produced. The Wagyu-like beef has a structure similar to original meat. This technology provides an alternative to natural meat harvesting methods if the livestock industry is plagued by disease. In addition, it provides a possible solution to reducing the environmental impact of the livestock industry. Bioremediation uses microorganisms or in recent times, materials of biological origin, such as enzymes, biocomposites, biopolymers, or nanoparticles, to biochemically degrade contaminants into harmless substances, making it an environmentally friendly and cost-effective alternative; 3D bioprinting facilitates the fabrication of functional structures using these materials that enhance bioremediation processes leading to a significant interest in the application of 3D bioprinted constructs in improving bioremediation.
Inspissation is the process used when heating high-protein-containing media; for example to enable recovery of bacteria for testing. Once inspissation has occurred, any stained bacteria, such as Mycobacteria, can then be isolated. A serum inspissation or fractional sterilization is a process of heating an article on 3 successive days as follows: In cystic fibrosis, inspissation of secretions in the respiratory and gastrointestinal tracts is a major mechanism causing the disease. Textbook of Microbiology by Prof. C P Baveja, ISBN 81-7855-266-3 Textbook of Microbiology by Ananthanarayan and Panikar, ISBN 81-250-2808-0
58. Adv Gerontol. 2002;9:95-100. [Tissue-specific action of peptides in tissue culture of rats of various ages]. [Article in Russian] Khavinson VKh(1), Malinin VV, Chalisova NI, Grigor'ev EI. Author information: (1)St. Petersburg Institute of Bioregulation and Gerontology, North-Western Branch, Russian Academy of Medical Sciences, 3, Dynamo Prospect, 197110 St. Petersburg, Russia. There was studied the effect of polypeptide preparations isolated from the cerebral cortex (Cortexin), epiphysis (Epithalamin), liver (Hepalin), thymus (Thymalin) and small synthetic peptides--Cortagen, Epitalon, Livagen, Vilon on the development of explants from the cerebral cortex, brain subcortical structures, liver and thymus of rats of various age. With respect to the applied concentrations of the investigated peptides, they exerted tissue-specific effects in the organ-typical culture of animal tissues.
Sources: en.wikipedia.org
== Religious considerations == The consumption of gelatin from particular animals may be forbidden by religious rules or cultural taboos. Islamic halal and Jewish kosher customs generally require gelatin from sources other than pigs, such as cattle that have been slaughtered according to religious regulations (halal or kosher), or fish (that Jews and Muslims are allowed to consume). On the other hand, Islamic jurists participating in a 1995 seminar held in Kuwait by the Islamic Organization for Medical Sciences have argued that the chemical treatment "purifies" or "transforms" the gelatin enough to always be halal. Furthermore, the principle of General Inescapable Necessity ('Umum al-Balwa) of the Sharia allows for even "non-purified" substances such as insulin derived from pig pancreas to be used when no alternative is immediately available. The same principle allows for using alcohol as a solvent in the production of food, with the added factor that very little alcohol actually remains in the product due to evaporation. It has similarly been argued that gelatin in medicine is permissible in Judaism, as it is not used as food. Orthodox Halachic opinions differ as to whether gelatin from non-kosher animals may be permitted to be used in regular food production, though the broad consensus among Orthodox kashrut authorities categorize it as non-kosher. Alternatives, such as gelatin from kosher animals and fish, despite being more expensive, are generally considered cost-effective due to the large market for kosher foods.
== Side effects == Side effects of lemborexant include somnolence or fatigue (combined preferred terms of somnolence, lethargy, fatigue, and sluggishness) (6.9% at 5 mg and 9.6% at 10 mg vs. 1.3% for placebo), headache (5.9% at 5 mg and 4.5% at 10 mg vs. 3.4% for placebo), and nightmares or abnormal dreams (0.9% at 5 mg and 2.2% at 10 mg vs. 0.9% for placebo). Less common side effects include sleep paralysis (1.3% at 5 mg and 1.6% at 10 mg vs. 0% for placebo) and hypnagogic hallucinations (0.1% at 5 mg and 0.7% at 10 mg vs. 0% for placebo). Lemborexant at doses of 10, 20, and 30 mg produces drug-liking responses similar to those of zolpidem (30 mg) and suvorexant (40 mg) in recreational sedative drug users. It is a controlled substance in the United States and is considered to have a low misuse potential.
== History == Lixisenatide is a GLP-1 receptor agonist that was created by Zealand Pharma A/S of Denmark; in 2003 Zealand licensed it to Sanofi which developed the drug. Lixisenatide was approved by the European Commission on 1 February 2013. Sanofi submitted an NDA in the US, which was accepted for review by the US FDA in February 2013 but after discussions with the FDA about the cardiovascular safety data included in the package (starting in 2008, the FDA had required stronger CV safety data for new anti-diabetes drugs, following the controversy around the risks of Avandia) Sanofi decided to withdraw the NDA and wait for the results of a Phase III study that was scheduled to be completed in 2015. Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. Lixisenatide received FDA approval on 28 July 2016. In 2010, Sanofi extended a license agreement it had with Zealand for lixisenatide to allow Sanofi to combine it with insulin glargine, which was Sanofi's best selling drug at the time, with sales of around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the new drug application in December 2015 for the combination and spent a US$245M priority voucher to gain a faster review, to try to outrace Novo Nordisk’s Xultophy, a similar combination drug of Novo's insulin Tresiba and Novo's GLP-1 agonist Victoza.
=== Women's rights and freedom of expression === The Houthis' treatment of women and their restrictions on the arts have been a subject of debate. On one side, the movement has stated that it defends women's rights to vote and take public offices, and some feminists have fled from government-held areas into Houthi territories as the latter at least disempower more radical jihadists. The Houthis field their own women security force, as well as a Girl Scouts wing. However, it has also been reported that Houthis harass women and restrict their freedom of movement and expression. In regards to culture, the Houthis try to spread their views through propaganda using mainstream media, social media, and poetry as well as the "Houthification" of the education system to "instil Huthi values and mobilise the youth to join the fight against the coalition forces". However, the Houthis have been inconsistent in regards how to deal with forms of artistic expression which they disapprove of. The movement has allowed radio stations to continue broadcasting music and content that the Houthis view as too Western, but also banned certain songs and harassed artists such as wedding musicians. In one instance, which generated much publicity, Houthi police officers stated that music could be played at a wedding party if loudspeakers did not broadcast it. The main wedding singer was arrested when the party guests did not conform to this demand. Journalist Robert F.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.